A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUSVACCINE IN HEALTHY PREGNANT INDIVIDUALS AND THEIR INFANTS
Clinical Trial Grant
Administered By
Obstetrics and Gynecology, Maternal Fetal Medicine
Awarded By
Pfizer, Inc.
Start Date
February 9, 2026
End Date
December 31, 2029
Administered By
Obstetrics and Gynecology, Maternal Fetal Medicine
Awarded By
Pfizer, Inc.
Start Date
February 9, 2026
End Date
December 31, 2029